Related Experiment Video
Updated: Apr 5, 2026
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
MRI in multiple sclerosis: progress in in-vivo pathobiology
Rosa Cortese1, Alessia Bianchi, Nicola De Stefano
1Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Purpose Of Review:
Recent advances in magnetic resonance imaging (MRI) have substantially expanded the ability to investigate multiple sclerosis (MS) pathobiology in-vivo. Beyond its diagnostic role, MRI now captures blood-brain barrier dysfunction, demyelination, neuroaxonal loss, glial activation, and network disruption across disease stages. This review is timely as accumulating evidence challenges a purely inflammation-driven ("outside-in") model of MS and supports interacting central nervous system-intrinsic ("inside-out") mechanisms that contribute to progression and disability.
Recent Findings:
Conventional MRI markers, such as gadolinium-enhancing lesions and T2 lesion burden, primarily reflect focal inflammatory activity. Advanced imaging techniques reveal diffuse tissue vulnerability, chronic active lesions, meningeal inflammation, metabolic dysfunction, and network failure, often independent of acute inflammation. These biomarkers bridge focal lesion pathology with smoldering, compartmentalized, and neurodegenerative processes.
Summary:
MRI supports a unified model of MS in which inflammatory, metabolic, and neurodegenerative mechanisms interact rather than follow a single linear cascade. Mechanistic MRI biomarkers enable biological stratification of patients, inform prognosis, and provide sensitive outcome measures for neuroprotective and remyelinating therapies, moving the field beyond lesion counting toward precision medicine.
Insights
Magnetic resonance imaging (MRI) advances reveal multiple sclerosis (MS) involves interacting inflammation, metabolic, and neurodegenerative mechanisms. Advanced MRI biomarkers track disease progression and aid in developing precision therapies for MS.
Area of Science:
- Neuroimaging
- Neurology
- Pathobiology
Background:
- Magnetic resonance imaging (MRI) has evolved beyond diagnostics for multiple sclerosis (MS).
- MRI now investigates in-vivo MS pathobiology, including blood-brain barrier dysfunction, demyelination, neuroaxonal loss, glial activation, and network disruption.
- Emerging evidence challenges the traditional inflammation-driven MS model, highlighting the role of central nervous system-intrinsic mechanisms.
Purpose of the Study:
- To review recent advances in MRI techniques for investigating MS.
- To discuss how advanced MRI markers reveal complex pathobiological processes in MS.
- To support a unified model of MS integrating inflammatory, metabolic, and neurodegenerative aspects.
Main Methods:
- Review of advanced magnetic resonance imaging (MRI) techniques and biomarkers.
- Analysis of conventional versus advanced MRI findings in multiple sclerosis (MS).
- Integration of imaging evidence with current understanding of MS pathobiology.
Main Results:
- Conventional MRI markers (e.g., enhancing lesions) reflect focal inflammation.
- Advanced MRI reveals diffuse vulnerability, chronic active lesions, meningeal inflammation, metabolic dysfunction, and network failure.
- These advanced biomarkers link focal pathology to chronic, smoldering, and neurodegenerative processes.
Conclusions:
- MRI supports a unified MS model where inflammatory, metabolic, and neurodegenerative mechanisms interact.
- Mechanistic MRI biomarkers allow for patient stratification and prognosis.
- Advanced MRI provides sensitive outcome measures for novel MS therapies, advancing precision medicine.
